This program is studying an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. An inhaled version could make it easier for someone with a Pseudomonas infection to take the drug from home. In addition, the drug, which targets the outer membrane of bacteria, has the potential to be a once-a-day treatment.

Status

A phase 1b/2a trial is planned to study inhaled murepavadin in adults with CF.

Sponsor

This program is sponsored by Spexis and partially funded by the Cystic Fibrosis Foundation.